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Abstract 
Reduced expression of the CDK inhibitor p27Kip1 (p27) in human lung cancer correlates with 
tumour aggressiveness and poor prognosis.  However, the regulation of p27 expression and 
the role of p27 during lung cancer are poorly understood.  Urethane-induced lung tumours in 
mice frequently harbor mutations in the Kras oncogene and here we use this model to 
address the regulation of p27 during tumorigenesis.  The Ras effector Akt is known to 
regulate p27 mRNA abundance by phosphorylating and inactivating the FOXO transcription 
factors.   Phosphorylated Akt and FOXO proteins were both increased in lung tumours, 
correlating with a reduction in p27 mRNA transcript.  Akt also directly phosphorylates p27 and 
regulates its nuclear/cytoplasmic localization.  Tumours showed a reduced 
nuclear/cytoplasmic ratio of p27 protein, together with an increase in phosphorylated Thr198 
p27 in the cytoplasmic pool.  Treatment of lung tumour-bearing mice with the 
phosphoinositol-3 kinase inhibitor LY294002 induced a rapid decrease in phosphorylated Akt 
and phosphorylated p27, concomitant with an increase in nuclear p27.  Germline p27 
deficiency accelerated both the growth and malignant progression of urethane-induced lung 
tumours, and did so in a cell autonomous manner, confirming a causal role of p27 in tumour 
suppression.  These results demonstrate that p27 is a potent barrier to the growth and 
malignant progression of Kras-initiated lung tumours.  Further, the reduction of nuclear p27 in 
tumours is mediated by oncogene signaling pathways, which can be reversed by 
pharmacologic agents. 
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Introduction 
One approach to cancer treatment is to enhance tumour suppressor activity in tumours.  The 
effectiveness of this strategy has been recently demonstrated using genetically engineered 
mouse models, where restoration of expression of a tumour suppressor, in this case p53, led 
to complete tumour regression (Ventura et al. 2007; Martins et al. 2006; Xue et al. 2007).  
This approach is currently not feasible in humans, the primary limitation being that most 
known tumour suppressors are mutated or deleted in tumours.  The Cdk inhibitor p27Kip1 
(p27) is a notable exception to the classic tumour suppressor gene paradigm in that the 
CDKN1B gene that encodes p27 is rarely mutated in tumours (Kawamata et al. 1995; Ponce-
Castaneda et al. 1995).  Instead, the levels of p27 protein are reduced or mislocalized and 
this correlates with tumour aggressiveness and poor prognosis (Chu et al. 2008).  A causal 
role for p27 in tumour suppression has been shown by the increased susceptibility of p27 
deficient mice to tumour development (Nakayama et al. 1996; Fero et al. 1996; Kiyokawa et 
al. 1996; Fero et al. 1998).  The fact that the gene encoding p27 remains intact in most 
human cancers, provides an opportunity to design therapies that might enhance expression 
of p27.  Key elements to the success of this strategy are to understand the mechanism(s) 
leading to misexpression of p27 and determine whether manipulating these pathways can 
enhance p27 expression in tumours.   
p27 abundance is regulated by a number of different pathways throughout the cell cycle.  The 
levels of p27 are high in quiescent cells and markedly reduced as cells transit through the cell 
cycle.  In S phase, p27 is phosphorylated at Thr187 by CDK2, targeting p27 for ubiquitination 
by SKP2 and subsequent degradation by the proteasome (Sheaff et al. 1997).  The KPC 
ubiquitin ligase was recently identified as a second mechanism to target p27 for degradation 
during G1 (Kamura et al. 2004).  Microinjection studies showed that active Ras can reduce 
p27 by three pathways: MAPK in G1, PI3K in G1 and S, and via increased SKP2 in S and G2 
(Sa and Stacey 2004).  Colorectal cancer cell lines exhibit proteasome-dependent 
degradation of p27 (Loda et al. 1997), and many tumours express high levels of its ubiquitin 
ligase, SKP2, suggesting that the levels of p27 in tumours are regulated by proteasomal 
degradation (Bloom and Pagano 2003).  Recent studies revealed that nonreceptor tyrosine 
kinases, such as Src, phosphorylate p27, consequently decreasing its stability (Chu et al. 
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2007; Grimmler et al. 2007), which may be yet another mechanism to reduce p27 abundance 
in tumours.    
In addition to decreasing overall p27 levels, exclusion of p27 from the nucleus and retention 
in the cytoplasm can effectively reduce its CDK inhibitory activity.  Cancers of the breast, 
thyroid, esophagus, and colon show specific reduction in nuclear p27, suggesting p27 
mislocalization may be important for tumour progression (Blain and Massague 2002).  At 
least two pathways have been proposed for nuclear export of p27 during G1 and S phase; 
association with Jab1, a component of the COP9-signalosome complex (Tomoda et al. 
1999), or direct binding to the transporter CRM1 via the nuclear export signal of p27 (Connor 
et al. 2003).  Nuclear export is regulated by the phosphorylation of p27 at specific residues.  
Ser10 phosphorylation of p27 by human kinase-interacting stathmin (hKIS or KIST) increases 
the binding of p27 to the nuclear exporter CRM1 (Boehm et al. 2002).   Experiments utilizing 
knock-in mice carrying a Ser to Ala mutation at position 10 of p27 showed reduced levels of 
p27 in cultured MEFs (Kotake et al. 2005) and impaired nuclear export of p27 (Besson et al. 
2006).  Phosphorylation of  Thr198, by either Akt or RSK1/2, results in binding to the protein 
14-3-3 and retention in the cytoplasm (Fujita et al. 2003).  This increases the stability of p27 
by preventing proteasomal turnover (Kossatz et al. 2006).  Cytoplasmic retention of p27 in 
human breast cancer cells was shown to be regulated by phosphorylation of Thr157 by the 
Akt kinase (Shin et al. 2005; Viglietto et al. 2002; Liang et al. 2002).  However, Thr157 is not 
present in rodent p27, so this pathway is not evolutionarily conserved.   
p27 is also regulated at the transcriptional levels.  In quiescent cells, FOXO proteins are 
located within the nucleus where they bind to the p27 promoter and initiate transcription 
(Dijkers et al. 2000).  In response to growth factors or oncogenic signals, FOXO proteins are 
phosphorylated by Akt, resulting in cytoplasmic sequestration, decreased p27 transcription, 
and cell proliferation (Medema et al. 2000).  As Akt is active in many tumours, this may 
represent an additional mechanism to reduce p27 during tumour growth. 
Lung cancer is among the leading causes of death worldwide and non-small cell lung cancer 
(NSCLC) accounts for ~87% of these cases (Singhal et al. 2005).  Reduced expression of 
p27 is seen in ~30% of NSCLC cases, and five independent studies have shown a significant 
correlation of reduced p27 with disease recurrence or death (Chu et al. 2008).  Mutations in 
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Kras and EGFR are frequently seen in lung cancer (Ding et al. 2008) and signaling from both 
can downregulate p27 in cell lines (Sa and Stacey 2004; Busse et al. 2000).  Inui et al. 
reported that p27 mRNA levels were not reduced in lung tumors, although these were not 
stratified by Ras mutational status or Akt activity (Inui et al. 2003).  Catzavelos et al. reported 
that Ras mutation and p27 expression seem to occur independently in adenocarcinoma of 
the lung (Catzavelos et al. 1999).  Thus, the mechanism(s) contributing to altered regulation 
of p27 during lung tumourigenesis are unclear.  
Urethane treatment of mice induces alveolar/bronchiolar adenomas and adenocarcinomas, 
which closely resemble human NSCLC adenocarcinoma in morphologic and molecular 
characteristics (Malkinson 2001).  Here we use this model to examine the role of p27 in lung 
tumour suppression and the mechanisms leading to its misregulation.  
 
Results 
p27-deficient mice are susceptible to non-small cell lung cancer  To establish an 
autochthonous tumour model to examine the role of p27 in lung cancer, cohorts of p27+/+, +/-
, and -/- littermates were injected with urethane.  The lung tumour incidence for all three 
genotypes was 100% at both 30 and 50 weeks.  At 30 weeks, both tumour multiplicity and 
tumour size were significantly greater in p27-/- and +/- mice compared to wildtype littermates 
(Figure 1A).  The average number of tumours greater than 1mm in diameter was 1.4 + 1.87, 
4.2 + 3.5, and 7.0 + 4.5 for p27+/+, +/- and  -/- mice, respectively (p het-wt = 0.026; p null-wt = 
0.0012; two-tailed t test).  Only four p27-/- mice survived beyond 40 weeks of age (median 
age 46 weeks), due to complications arising from excess lung tumour burden and pituitary 
tumours, and data from these four mice are included in the 50 week graph (Figure 1B).  
Tumour burden was greater at 50 versus 30 weeks for all genotypes.  Again, tumour 
multiplicity and size were both increased in p27 deficient mice compared to wildtype 
littermates (Figure 1B, 1D).  The average number of tumours per mouse at 50 weeks of age 
in p27 intact mice was similar to the number in p27-/- mice at 30 weeks of age (Figure 1C), 
suggesting that the primary effect of p27 is to inhibit tumour growth as opposed to tumour 
initiation.   
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Since the tumour burden of p27+/- mice was increased relative to p27+/+ mice, we examined 
the p27 locus for loss of heterozygosity.  Analysis of tumours from p27+/- mice showed 
retention of the wildtype p27 allele in all 24 tumours examined (Figure 1E), consistent with 
previous findings that p27 is haploinsufficient for tumour suppression (Fero et al. 1998).   
Histological evaluation revealed that the majority of tumours were alveolar/bronchiolar 
adenomas that displayed papillary, solid, or mixed morphologies.  In p27 intact mice, 
adenocarcinomas were not seen until 50 weeks of age, while both p27 null and heterozygous 
mice developed an average of one malignant tumour per mouse by 30 weeks of age (Figure 
1F).  These tumours where characterized by marked cellular atypia and local invasion 
indicating that p27 deficiency increased both tumour growth and malignant tumour 
progression.  
Tumour suppression by p27 is cell autonomous  Detection of mutations in cancer genes 
in tumours is evidence for a cell autonomous mechanism of action.  However, mutations in 
the CDKN1B gene encoding p27 are rarely observed in tumours.  Forced expression of p27 
can inhibit tumour cell proliferation, and mice lacking p27 are tumour prone.  However, this 
evidence is insufficient to prove that p27 suppresses tumours through a cell autonomous 
mechanism and other approaches are required to establish this conclusively. We used a 
neonatal lung tissue transplantation model to address this.  Lung tissue from neonatal p27 
deficient or wildtype mice was transplanted to the ear of adult wildtype recipients.  After 
engraftment, mice were treated with urethane and transplant size was measured up to 30 
weeks.   Tumours developed from ~50% of transplants from p27-/- (10/19) or p27+/- mice 
(19/39), compared to only 25% (5/20) from p27+/+ mice (Figure 2A). Tumours were larger 
from both p27-/- and p27+/- transplants (Figure 2B). Histologic evaluation indicated that the 
majority of tumours were bronchioalveolar adenomas and carcinomas.  Thus, cells lacking 
p27 are more susceptible to tumourigenic outgrowth than are p27 intact cells, indicating a cell 
autonomous mechanism of tumour suppression by p27 . 
Mutation of Kras in urethane-induced lung tumours  Sequence analysis of lung tumour 
DNA revealed that 80% of urethane-induced tumours had a CAA to CTA transversion 
mutation at codon 61 of the Kras gene, resulting in a Q61L amino acid change (Figure 3A). 
The frequency of this mutation was similar in tumours from A/J, B6, and B6/129 strains.  The 
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frequencies of Kras mutations were also similar in tumours from p27+/+, +/- and -/- mice 
(Figure 3B).   
Nuclear exclusion of p27 protein in lung tumours  Since p27 deficient mice showed 
increased susceptibility to urethane-induced lung tumours, we examined the status of p27 
protein in lung tumours from p27 intact mice.  Staining of tissue sections with a monoclonal 
anti- p27 antibody revealed prominent nuclear p27 staining in normal lung parenchymal cells 
but reduced nuclear p27 in tumour cells (Figure 4A).  Western blot analysis of nuclear and 
cytoplasmic fractions prepared from frozen tissues revealed that tumours exhibit reduced 
nuclear p27 while retaining the cytoplasmic pool (Figure 4B).  Quantitation with densitometry 
confirmed the ratio of nuclear to cytoplasmic p27 was markedly reduced in tumours 
compared to normal lung (Figure 4C).  Therefore, both mutation of Kras and aberrant 
subcellular localization of p27 protein are cardinal features of this tumour model. 
As both Ras mutation and altered p27 expression are consistently observed together, we 
asked whether oncogenic signals emanating from mutant Ras protein actively drive p27 
mislocalization. We compared the phosphorylation status of specific residues of p27 (Ser10, 
Thr187, and Thr197) shown to be involved in regulation of cellular localization, as well as 
upstream candidate regulators between normal lung and tumour lysates.   
Ras signaling is expected to induce cyclin D1, activate Cdk2 and drive cell cycle progression.  
Cdk2, in turn, is known to phosphorylate residue Thr187, targeting p27 for Jab1-mediated 
export and Skp2 degradation (Sheaff et al. 1997).  We found an increase in both cyclin D1 
and Cdk2 kinase activity in tumour extracts, consistent with the enhanced proliferation of lung 
tumour cells (Figure 5A).  We also observed an increase in Jab1 and Thr187 phospho- p27 in 
cytoplasmic fractions of lung tumours (Figure 5B), leading to the conclusion that Cdk2-
dependent phospho-Thr187 p27 is exported and accumulates in the cytoplasm.  The 
cytoplasmic levels of two ubiquitin ligases for p27, Skp2 and Kpc, were similar between 
tumour and normal tissue, suggesting that proteasome degradation via upregulation of Skp2 
or Kpc may not be the major pathway to regulate p27 abundance in this tumour model. 
Ras also signals through PI3K to activate Akt, which in turn can phosphorylate p27 at multiple 
sites including Ser10, Thr157 (in human but not in mouse), and Thr198 (Thr197 in the 
mouse), each of which has been shown to promote nuclear to cytoplasmic shuttling (Susaki 
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and Nakayama 2007).  Phosphorylated Ser10 p27 was found in nuclear and cytoplasmic 
fractions and did not appear to differ between normal and tumour extracts (Figure 5C).  
However, as total nuclear p27 is markedly reduced in nuclear fractions from tumours, the 
proportion of p27 that is phosphorylated within tumour nuclear pools could be increased. 
Levels of phospho-Thr198 p27 were markedly increased in lung tumours, notably in the 
cytoplasmic fraction (Figure 5C).  The levels of 14-3-3, which binds to cytoplasmic p27 
phosphorylated at Thr198 (Fujita et al. 2003) were also modestly elevated, suggesting a 
plausible scenario of Akt dependent phosphorylation of Thr198 p27 and cytoplasmic retention 
of p27 by 14-3-3.  These data together indicate p27 is phosphorylated at multiple sites in lung 
tumours, one or more of which could signal nuclear export and cytoplasmic retention.  
Reduction of p27 transcript in lung tumours   While most studies have focused on post 
translational regulation of p27 abundance, transcriptional control is also documented (Philipp-
Staheli et al. 2004).  Quantitative real time PCR revealed a five to ten fold reduction in p27 
mRNA transcript in 13 out of 13 lung tumours examined, as compared to normal lung tissue 
(Figure 6A).  Signaling from Ras has been linked to p27 transcription via Akt dependent 
phosphorylation of Forkhead transcription factors (Medema et al. 2000).  Lung tumour 
extracts showed an increase in active phospho-Akt (Figure 5C), as well as phosphorylated 
cytoplasmic FOXO1 and FOXO3a.  Phosphorylated  FOXO4a, by contrast, shows equivalent 
expression in tumour and normal lung (Figure 6B).  These data are consistent with the idea 
that oncogenic Kras signaling through PI3K activates Akt, which phosphorylates FOXO 
transcription factors, resulting in their retention in the cytoplasm, thereby reducing p27 
transcription.   
In summary, p27 expression in lung tumours is altered in at least two ways: increased 
phosphorylation leading to nuclear exclusion, and reduced transcription.  Both mechanisms 
could be due to Ras signaling through Akt. 
Inhibition of PI3K and Akt restores p27 levels in tumours  Since the gene encoding p27 
is intact in tumours, we asked whether its expression could be restored by pharmacologically 
blocking pathways leading to its misregulation.  As Akt plays a role in both transcriptional and 
posttranslational regulation of p27, we used the PI3K inhibitor LY294002 to inhibit this 
pathway.  Treatment of the mouse lung tumour cell line SP10 with LY294002 led to a 
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reduction of phospho-Akt, a reduction in phospho-FOXO, and an increase in both p27 
transcript and protein levels (Figure 7A, B).  Therefore, inhibition of the PI-3 Kinase pathway 
can enhance p27 levels in tumour cells by increasing p27 transcription.   
We next treated tumour-bearing A/J mice with LY294002 and analyzed tumours for short 
term changes in Akt signaling and p27 expression.  Western blot analysis of tumour lysates 
showed a marked reduction of phospho-Akt and phosphorylated FOXO in inhibitor treated 
mice compared to tumours from vehicle treated mice (Figure 7C), while total cellular levels of 
Akt remained unchanged.  This shows that LY294002 treatment effectively inhibited the PI-
3K to Akt to FOXO signaling cascade in lung tumours in vivo.  Next, we examined p27 
expression and phosphorylation.  LY294002 treatment reversed the nuclear exclusion of p27 
in tumours, as revealed by both Western blots of tumour lysates (Figure 7C) and 
immunohistochemistry of lung tumour sections (Figure 7D).  Relative to untreated tumours, 
tumours from LY294002 treated mice showed equal nuclear/cytoplasmic distribution of p27 
and more prominent nuclear staining for p27.  Since LY294002 inhibits Akt, and Akt can 
phosphorylate p27 directly, we examined the phosphorylation status of p27.  Western blotting 
of lysates from inhibitor treated tumours showed a reduction in both cytoplasmic phospho-
Thr198 and phospho-Ser10 p27  (Figure 7E).  Together, these findings indicate that aberrant  
expression of p27 in tumours is an active processes regulated by the PI3K-Akt pathway, and 
that the mislocalization of p27 in tumours can be reversed through the use of pathway 
specific inhibitors.     
 
Discussion 
These studies demonstrate that p27 acts as a barrier to the growth and malignant 
progression of Kras driven NSCLC.  Both homozygous and hemizygous germline deletion of 
p27 led to an increase in both the size and malignancy of tumours.  The observation that the 
average number of tumours in wild type mice at 50 weeks was similar to the number of 
tumours in p27 deficient mice at 30 weeks, together with the observation that tumour 
suppression by p27 is cell autonomous, argues that the primary effect of p27 is to inhibit the 
clonal expansion of initiated tumour cells.  Tumours from all p27 genotypes harbored 
mutations in the Kras oncogene, establishing that p27 specifically inhibits Kras-driven tumour 
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growth.  The ubiquitous reduction of nuclear p27 in tumours further implies that cell cycle 
inhibition by p27 is a critical barrier to be overcome for such clonal expansion.   
p27 and malignant progression  In addition to inhibiting tumour growth, p27 suppressed 
malignant lung tumour progression.  By 30 weeks of age, 67% of p27 deficient mice had 
malignant disease, averaging one adenocarcinoma per mouse, while no carcinomas were 
observed in p27 intact mice.  It is at present not clear whether this is due to increased tumour 
growth, leading to an increase in rate of tumour evolution toward malignancy, or is a more 
direct consequence of p27 functions; e.g. due to loss of differentiation or increased invasion.  
p27 can induce cell differentiation in vitro (reviewed in (Philipp-Staheli et al. 2001)), and p27 
deficiency leads to impaired differentiation of several cell types in vivo (Casaccia-Bonnefil et 
al. 1997; Nakayama et al. 1996; Zindy et al. 1999; Tong et al. 1998).  Although the 
mechanisms by which p27 can trigger differentiation are poorly understood, p27 induced cell 
cycle exit appears to be tightly linked to terminal differentiation.  p27 also plays a role in cell 
migration, independent of its Cdk inhibitory function (Besson et al. 2004a).  p27 has been 
shown to inhibit cancer cell invasion (Yuan et al. 2007; Schiappacassi et al. 2008) by binding 
to microtubule destabilizing protein, stathmin (Baldassarre et al. 2005).  On the other hand, a 
promigratory role for cytoplasmic p27, through interaction with the Rho family of GTPases 
and the cytoskeleton, has also been described (McAllister et al. 2003; Besson et al. 2004b).  
Hence, tumours with reduced or mislocalized p27 may have impaired capacity to differentiate 
and/or enhanced migratory ability thereby increasing their malignant behavior.     
Malignant tumour progression due to reduced p27 has been documented in other mouse 
cancer models (Philipp et al. 1999; Philipp-Staheli et al. 2002; Shaffer et al. 2005), indicating 
this is a characteristic trait of tumour suppression by p27.  In human cancer, including 
NSCLC, reduced p27 expression correlates with higher tumour grade and stage, features 
which incorporate differentiation, invasion and metastasis (Chu et al. 2008).  Together, this 
indicates that p27 is a barrier to malignant progression and the misregulation of p27 in 
tumours is causally linked to tumour aggressiveness. 
p27 misregulation in tumours  Having established that p27 inhibits both the growth and 
malignant progression of NSCLC, we next examined the mechanism by which tumours 
circumvent p27.  Lung tumours showed a consistent reduction in the nuclear pool of p27, 
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while largely retaining cytoplasmic expression, as well as a marked reduction of mRNA 
transcript.  Thus, transcriptional control as well as subcellular localization contribute to a 
reduction of nuclear p27 in tumours, which can lead to increased CDK activity.  Activating 
mutations in Kras were also cardinal features of this tumour model, suggesting a mechanistic 
link between Kras signaling and p27 loss.  Indeed, an emerging model to explain the basis of 
cooperation between oncogene activation and tumour suppressor gene loss posits that 
oncogenes directly signal to tumour suppressor genes.  The Ras effector, Akt, has been 
shown to regulate p27 at multiple levels, so we asked whether p27 misregulation in tumours 
is a direct consequence of Akt signaling.  p27 can be barred from the nucleus by pathways 
involving phosphorylation at Ser10, Thr157 (human but not mouse), and Thr198, all of which 
have been reported as Akt targets.  We did not observe significant changes in abundance of 
phospho-Ser10 p27 in lung extracts.  However, as the total nuclear p27 levels were 
decreased in tumours, it is possible that the ratio of phospho-Ser10 p27 to total p27 is 
increased in these tumours.  Akt can also phosphorylate p27 on Thr198 and promote binding 
to 14-3-3 in the cytoplasm (Fujita et al. 2003; Motti et al. 2005; Motti et al. 2004).   Lung 
tumours showed a marked increase in phospho-Thr198 p27, specifically in the cytoplasmic 
pool, together with a modest increase in 14-3-3, suggesting phospho-Thr198 may direct 
nuclear export and increase stability of p27 in the cytoplasm.  Indeed, inhibition of Akt in both 
mouse lung tumour cell lines and in tumour-bearing mice led to a reduction in phospho-Ser10 
and phospho-Thr198 p27 and redistribution of p27 to the nucleus.   
Akt is also a key player in mediating signaling from Ras through the FOXO transcription 
factors to regulate p27 transcription (Medema et al. 2000).  Increased phosphorylation of 
FOXO proteins was seen in cytoplasmic fractions from lung tumours, correlating with reduced 
p27 mRNA levels.  LY294002 reduced phosphorylation of both Akt and FOXO and increased 
p27 transcript and nuclear p27 protein levels.  Together these findings demonstrate that Ras 
signaling through the PI3K/Akt pathway regulates p27 abundance and localization at both the 
transcriptional and post-translational levels.   
In summary, p27 acts as a potent barrier to Kras initiated NSCLC that must be overcome for 
efficient clonal expansion and malignant progression.  However, in contrast to most known 
tumour suppressors which are inactivated by mutation, p27 reduction is an active and 
reversible process; in this case, mediated by oncogenic signaling.  If a similar mechanism 
 12 
occurs in human lung cancer, this would create a window of opportunity for therapeutic 
intervention.   
 
Materials and methods 
Mice  Experiments were approved by the FHCRC Institutional Animal Care and Use 
Committee.  Two cohorts of 129 x C57BL/6J F1 p27-/-, p27+/-, and p27+/+ mice (Fero et al. 
1996) as well as C57BL/6J and A/J mice were treated with urethane (1mg/g bodyweight, i.p.) 
at 12 days of age.    Cohorts were sacrificed at  30 or 50 weeks of age.  Tumours visible on 
the surface of all lung lobes were counted and measured using a dissecting microscope.  
Normal and tumour tissues were either snap frozen in liquid nitrogen for DNA, RNA, and 
protein extraction or fixed in neutral buffered formalin.  Fixed tissue was processed and 
stained with H&E for histological examination. DNA for genotyping was obtained by digestion 
of tissue with proteinase K in InstaGene Matrix solution (Bio-Rad, Hercules, CA, USA). Each 
mouse was genotyped by PCR using primers specific for the wild-type or neo interrupted p27 
locus (Fero et al. 1996). 
Kras sequence analysis  Genomic DNA was isolated from lung tumours using the QIAGEN 
QIAamp DNA mini kit.  The Kras locus at codon 61 was amplified using primers 5’-
GACTCCTACAGGAAACAAGT-3’ and 5’–GAAGATATTCACCATTATAG-3’ (You et al. 1989) 
by PCR and sequenced using the Big Dye Sequencing protocol (PE-Biosystems). 
Western blot analysis  Nuclear and cytoplasmic protein extracts were prepared as 
described (Schreiber et al. 1989), with modifications (Philipp-Staheli et al. 2002).  Protein 
concentrations were standardized using the Bradford assay (BioRad), and equal loading was 
confirmed by Ponceau S staining of PVDF membranes after blotting (Immun-BlotTM PVDF 
membrane, BioRad).  The following antibodies were used for Western blotting: p27 (sc-528), 
phospho- Thr187 p27 (sc-16324), phospho- Ser10 p27 (sc-12939), cyclinD1 (sc-755), cdk2 
(sc-163), Jab1 (sc-9074), 14-3-3 θ (sc-732), β-tubulin (sc-9104) and lamin B1 (sc-20682) 
were from Santa Cruz Biotechnology (Santa Cruz, CA).  p45/Skp2 antibody (ab19877) was 
purchased from Abcam and the phospho-Thr198 p27 purchased from R&D Systems 
(AF3994). The anti-KPC1 antibody (H00063891-A01) was obtained from Novus Biologicals. 
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Akt phospho-specific (9271, 9275) and FOXO family (9464, 9466, 9471) antibodies were 
purchased from Cell Signaling (Beverly, MA).  
Histopathology and immunohistochemistry   Lung lobes with embedded tumours were 
removed and fixed in 10% neutral buffered formalin for 4-6 h, processed and embedded in 
paraffin.  Step sections were made, with every fifth section stained with H&E for the most 
accurate histologic quantification of tumour multiplicity and malignancy.  All slides were 
reviewed by a pathologist (SK) blind to the genotype.  Diagnosis of adenoma was based on 
discrete, well demarcated foci consisting of a uniform population of epithelial cells with round 
nuclei and a moderate amount of eosinophilic cytoplasm.  Compared with adenomas, 
adenocarcinomas showed greater cellular atypia, regional variation of growth patterns, 
increased mitotic activity, and local invasion into adjacent bronchioles or vessels. 
Immunohistochemistry for p27 was performed as described (Philipp-Staheli et al. 2002) using 
a mouse monoclonal antibody from Neomarkers (Fremont, CA).  Controls included no 
primary antibody and/or normal rabbit serum, and tissues from p27 null mice.   
Histone kinase assay  Protein extracts were prepared as described above and stored in 
50% glycerol. 400 μg of protein were incubated on ice in 500 μl RIPA buffer containing Cdk2 
antibody. Then 30 μl of washed Protein A-Sepharose beads were added, and the reaction 
was rotated for 1 h at 4  C. Beads were washed twice in RIPA and once in a buffer containing 
25 mM Tris HCl (pH 7.5), 70 mM NaCl, 10mM MgCl2, and 1 mM DTT. The beads were then 
incubated with Histone H1 as a substrate and 32P-γATP for 30 min at 37  C. The reaction was 
stopped by the addition of sample buffer, denatured for 5 min at 95  C, and the protein 
separated on a 12% SDS acrylamide gel run for 45 min at 150 volts. The gel was washed, 
fixed and exposed to X-ray film to visualize bands. 
Real-time PCR assay  The relative levels of p27 mRNA were assessed using RTPCR as 
described (Philipp-Staheli et al. 2004), using the forward primer 5’-
AGGCTGGGTTAGCGGAGC-3’; reverse primer 5’-GAACCGTCTGAAACATTTTCTTCTGT-
3’; and probe 5’ FAM-ACCTTGCTGCAGAAGATTCTTCTTCGCAA-TAMRA 3’.     
Tumour DNA isolation and LOH analysis DNA was extracted from frozen tumours using 
BioRad InstaGene Matrix and p27 PCR conditions are available on request.  PCR products 
were run on a 1% agarose gel stained with ethidium bromide. 
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Ear engraftment  Lungs were removed from neonatal mice derived from NIH p27+/- x 
B6/129 p27+/- crosses and cut into 2mm3 sections and kept on ice.  Recipient NIH wild type 
adult mice were anesthetized with avertin.  A small pouch was made in both ears using a 
scalpel and scissors.  A 2 mm3 section of lung was inserted, and the pouch sealed with super 
glue.  For a given recipient, transplant of a different p27 genotype in each ear served as a 
control.  Mice were injected with urethane once a week for 6 weeks (0.25 mg/g body weight 
i.p.). The ear grafts were measured every other week and mice were sacrificed at 30-38 
weeks, and tissues processed as described above.   
PI3K inhibition  SP10 lung tumour cells (ATCC), derived from a spontaneous lung tumour 
from an A/J strain mouse, were grown to 70% confluence, serum starved overnight, then 
serum containing media with 50 μg/ml LY294002 (Sigma) was added.  Cells were harvested 
at 1, 2, 4, 6, and 18 h post-treatment and whole cell lysates were made using buffer 
containing 150 mM NaCl, 50 mM Tris pH 8, and 1% NP-40.  Cells not subjected to serum 
starvation or inhibitor treatment were used as controls in Western analysis.  For in vivo 
studies, nine month old lung tumour-bearing A/J mice were injected with LY294002 (100 
mg/kg body weight, i.p.) or DMSO three times over a six hour period.     
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Titles and legends to figures 
Figure 1.  p27 is a lung tumour suppressor  Histogram comparing the number and sizes of 
urethane-induced lung tumours in p27+/+, +/-, and -/- mice at (A) 30 weeks and (B) 50 weeks 
post-treatment.  Only four p27 null mice survived to a median age of 46 weeks and the 
tumour counts from these mice are graphed in (B).   (C)  Table showing mean number of 
tumours per mouse according to genotype and age.  (D) Photograph of lungs from p27+/+ 
and p27-/- mice showing increased tumour burden in p27-/- lungs. (E) Loss of heterozygosity 
analysis of DNA from tumours from p27+/- mice, n= 24 tumours examined in total.  DNA from 
p27+/+ and -/- tumours are shown as controls. wt= wild type p27 allele. mu= knockout p27 
allele.  (F) Histogram showing mean number of adenocarcinomas per mouse at 30 and 50 
weeks of age.  Insufficient numbers of p27-/- mice survived to 50 weeks, so these are not 
shown. Shown are p values from unpaired t-test for comparisons between genotypes. (G) 
Photomicrographs of lung sections with an alveolar/bronchiolar adenoma from a p27+/+ 
mouse (left) and an adenocarcinoma from a p27-/- mouse (right).  Note the discrete boundary 
between adenoma and normal lung (clear arrow) and monomorphic, orderly tumour cells 
(clear arrowhead), compared to invasive tumour cells of the adenocarcinoma into lung 
parenchyma and local airway (black arrows) and pleomorphic appearance of tumour cells 
(black arrowheads).  
Figure 2. Tumour suppression by p27 is cell autonomous  Lung tissue from p27+/+, +/-, 
or -/- mice was transplanted to the ears of wild type recipients.  After engraftment, mice were 
then treated with urethane and transplant size was measured up to 30 weeks (p27+/+ n=14, 
p27+/- n=23, p27-/- n=14).  (A) Bar graph shows percent transplants that developed tumours. 
(B) Size of transplanted tumours at 30 weeks. Each symbol represents one transplant.  
Figure 3. K-ras mutations are frequent in lung tumours  (A) The chromatograms show the 
Kras wildtype sequence (left) and an CAA>CTA mutation in codon 61 (right) from a tumour. 
(B) Table shows frequency of K-ras mutations in tumours from different genetic backgrounds 
and p27 status.   
Figure 4. Nuclear p27 is reduced in lung tumours  (A) Photomicrograph of a lung 
adenoma section from a wild type mouse stained with a p27 antibody.  Note strong nuclear 
staining in normal lung parenchymal cells and reduced nuclear staining in tumour cells.  (B)  
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Western blot of extracts from lung tumours and normal lung from wild type mice probed with 
p27 antibody.  n: nuclear extracts, c: cytoplasmic extracts.  p27 antibody specificity is 
indicated by tissue from p27 null mouse (-/-) as a negative control.  (C) Quantitation of 
nuclear (n) to cytoplasmic (c) p27 protein expression from Western blots of normal and 
tumour lysates. Numbers show median values of n/c ratios. 
Figure 5. Posttranslational regulation of p27 in lung tumours  (A) Increased Cdk2 activity 
in lung tumours from wild type mice versus normal lung using histone H1 as a substrate.  
Western blot of whole cell lysates shows Cdk2 protein levels unchanged and an increase in 
cyclin D1 in lung tumours compared to normal lung. (B) Western blot of total p27, phospho-
T187 p27, Jab1, KPC, and Skp2 in tumours and normal lung, with lamin B1 and β-tubulin as 
nuclear and cytoplasmic fractionation controls.  Note increase in p-T187 p27 in cytoplasmic 
fractions compared to normal lung. n: nuclear extracts, c: cytoplasmic fractions. (C) Western 
blot of p-T198 p27, p-S10 p27, and 14-3-3-θ.  Note increased p-T198 p27 in cytoplasmic 
tumour fractions.   
Figure 6. Reduced p27 transcript and increased p-Akt and p-FOXO in lung tumours  (A) 
Bar graph of p27 mRNA expression levels derived from real-time PCR using total RNA 
isolated from lung tumours and normal lung (NL) from wild type mice.  (B) Western blot 
shows expression levels of phosphorylated forkhead family members, p-FOXO1, p-FOXO3a, 
and p-FOXO4a in lung tumour extracts compared to normal lung. n: nuclear extracts, c: 
cytoplasmic fractions.  
Figure 7. Inhibition of the PI3K pathway increases nuclear p27 in tumours (A) Time 
course analysis of effects of LY294002 (LY) on SP10 mouse lung tumour cell line.  Shown 
are Western blots of cell lysates probed with antibodies to p-Akt, p-FOXO, and p27 at the 
indicated times after addition of serum and LY.  The control (ctrl) lane is from cells not serum 
starved. (B)  Real-time PCR of p27 mRNA from treated (+LY) and control (-LY) treated SP10 
cells 8 and 24 h after start of PI3K inhibition.  (C) Western blot of total and p-Akt, p-FOXO, 
and p27 in lung tumours from wild type mice 5 h after treatment with LY. n: nuclear extracts, 
c: cytoplasmic fractions.  (D) Sections of representative lung tumours immunostained for p27 
shows increase in nuclear p27 following LY294002 treatment.  (E) Western blot of tumour 
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lysates shows decreased p-T198 p27 and p-S10 p27 in LY294002 treated lung tumours. 
Lamin B1 is nuclear fraction loading control.  N.Lung = normal lung.   







